Loading clinical trials...
Loading clinical trials...
The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+ Chronic Myeloid Leucemia (CML) in Early Chronic Phase: a Phase II Exploratory, Multicenter Study. GIMEMA Protocol CML 0307. EUDRACT 2007-000597-22.
Conditions
Interventions
Nilotinib
Locations
22
Italy
Dipartimento Area Medica P.O.
Ascoli Piceno, Italy
Unità Operativa Ematologica - Università degli Studi di Bari
Bari, Italy
Ospedali Riuniti
Bergamo, Italy
stituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi
Bologna, Italy
Sezione di Ematologia e Trapianti Spedali Civili
Brescia, Italy
Azienda Spedali Civili
Brescia, Italy
Start Date
June 23, 2007
Primary Completion Date
April 30, 2018
Completion Date
April 30, 2018
Last Updated
January 18, 2022
NCT06514534
NCT05143840
NCT06994676
NCT06523556
NCT06236724
NCT04195633
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions